COMPARISON OF EFFICACY OF CLOMIPHENE CITRATE ALONE AND WITH GLUCOPHAGE FOR TREATMENT OF INFERTILITY IN POLYCYSTIC OVARIAN SYNDROME
Objective: To compare the efficacy of clomiphene citrate alone and with Glucophage for treatment of infertility in polycystic ovarian syndrome.
Materials and methods: This randomized control trial was done during six months from May 2019 to November 2019 at department of Gynaecology and Obstetrics, Bahawal Victoria Hospital, Bahawalpur. All the married infertile women with polycystic ovarian syndrome of >6 months of duration, 20 to 35 years of age were included and were divided in two groups. Clomiphene citrate tablet was given in dose of 50mg, 100mg, and 150mg for three consecutive menstrual cycles in both groups for 5 days starting from 2nd day of menstrual cycle. Metformin tablet was given in dose 500mg three times a day throughout the menstrual cycle in group B only. Efficacy was measured in terms of conception for three consecutive menstrual cycles by positive urine pregnancy test and was confirmed on ultrasonography. All the data was recorded via study proforma and 26 version of SPSS was used for data analysis.
Results: A total of 114 married infertile women were studied. Average age of women of group A was 30.12 ± 4.33 years and of group B was 29.54 ± 4.76 years. Mean duration since marriage was 4.23 ± 1.42 years and average duration of PCOS was 10.31 ± 2.57 months. Overall average of BMI was 29.75 ± 2.65 kg/m2. Efficacy was seen in 35.09% patients in clomiphene citrate only group and in 63.16% in the clomiphene citrate plus metformin group (p- 0.003).
Conclusion: Combined clomiphene citrate and metformin therapy was observed to be the more effective in the treatment of infertility in polycystic ovarian syndrome compared to clomiphene citrate alone therapy.
Keywords: Polycystic ovarian syndrome, clomiphene citrate, metformin.
Copyright (c) 2022 Journal of The Society of Obstetricians and Gynaecologists of Pakistan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.